Regioselectively oxidized hyaluronate for enhanced cisplatin delivery

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F70883521%3A28610%2F22%3A63560499" target="_blank" >RIV/70883521:28610/22:63560499 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Regioselectively oxidized hyaluronate for enhanced cisplatin delivery

Popis výsledku v původním jazyce

Severe side effects ofplatinum anticancer complexes led to the developrnent of various drug delivery strategies, including their conjugation to polysaccharide carriers, which offer excel!ent biocompatibility, biodegradability, and potential for targeting malignancies. However, only several polysaccharides can directly bind anticancer drugs, and these often have a low density of suitable biding groups. For instance, hyaluronate (HA) has cisplatin (CP) loading efficacy of only -50% and a loading capacity limited to 25 wt.%, because each molecule of CP requires two units of HA to bind. The resulting crosslinking also limits the conjugate solubility. Modifications aimed to improve these issues are usually centered around the COOH group of HA, which, however, impairs its ability to bind to the proteoglycan receptor CD44, thus negating one of HA&apos;s greatest advantages as a drug carrier -tumor targeťing. Hence, a sequential regioselective oxidation scheme, that introduces a pair of carboxylic groups at C2 and C3 of glucuronate has been developed and advantages of prepared 2,3-dicarboxy hyaluronate (DCH) over unmodified HA as a carrier for CP are demonstrated.The regioselective oxidation ofHA essentially triples the amount of available -COOH groups in its structure, greatly improving its capabilities as a CP carrier without modifying the N-acetyl glucosamine unit or C6 of glucuronate. DCH also possesses a large potential for further modifications.

Název v anglickém jazyce

Regioselectively oxidized hyaluronate for enhanced cisplatin delivery

Popis výsledku anglicky

Severe side effects ofplatinum anticancer complexes led to the developrnent of various drug delivery strategies, including their conjugation to polysaccharide carriers, which offer excel!ent biocompatibility, biodegradability, and potential for targeting malignancies. However, only several polysaccharides can directly bind anticancer drugs, and these often have a low density of suitable biding groups. For instance, hyaluronate (HA) has cisplatin (CP) loading efficacy of only -50% and a loading capacity limited to 25 wt.%, because each molecule of CP requires two units of HA to bind. The resulting crosslinking also limits the conjugate solubility. Modifications aimed to improve these issues are usually centered around the COOH group of HA, which, however, impairs its ability to bind to the proteoglycan receptor CD44, thus negating one of HA&apos;s greatest advantages as a drug carrier -tumor targeťing. Hence, a sequential regioselective oxidation scheme, that introduces a pair of carboxylic groups at C2 and C3 of glucuronate has been developed and advantages of prepared 2,3-dicarboxy hyaluronate (DCH) over unmodified HA as a carrier for CP are demonstrated.The regioselective oxidation ofHA essentially triples the amount of available -COOH groups in its structure, greatly improving its capabilities as a CP carrier without modifying the N-acetyl glucosamine unit or C6 of glucuronate. DCH also possesses a large potential for further modifications.

Druh

O - Ostatní výsledky

CEP obor

—

OECD FORD obor

10404 - Polymer science

Projekt

<a href="/cs/project/EF16_028%2F0006243" target="_blank" >EF16_028/0006243: Rozvoj kapacit pro výzkum a vývoj UTB ve Zlíně</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2022

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů